182 related articles for article (PubMed ID: 9079753)
21. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.
Gorgoulis VG; Rassidakis GZ; Karameris AM; Papastamatiou H; Trigidou R; Veslemes M; Rassidakis AN; Kittas C
Mod Pathol; 1996 May; 9(5):544-54. PubMed ID: 8733770
[TBL] [Abstract][Full Text] [Related]
22. Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma.
Cho DS; Joo HJ; Oh DK; Kang JH; Kim YS; Lee KB; Kim SJ
Yonsei Med J; 2005 Feb; 46(1):133-40. PubMed ID: 15744816
[TBL] [Abstract][Full Text] [Related]
23. p53 pathway in renal cell carcinoma is repressed by a dominant mechanism.
Gurova KV; Hill JE; Razorenova OV; Chumakov PM; Gudkov AV
Cancer Res; 2004 Mar; 64(6):1951-8. PubMed ID: 15026329
[TBL] [Abstract][Full Text] [Related]
24. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
[TBL] [Abstract][Full Text] [Related]
25. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma.
Moch H; Sauter G; Buchholz N; Gasser TC; Bubendorf L; Waldman FM; Mihatsch MJ
Hum Pathol; 1997 Nov; 28(11):1255-9. PubMed ID: 9385930
[TBL] [Abstract][Full Text] [Related]
27. Abnormal expression of MDM2 in prostate carcinoma.
Leite KR; Franco MF; Srougi M; Nesrallah LJ; Nesrallah A; Bevilacqua RG; Darini E; Carvalho CM; Meirelles MI; Santana I; Camara-Lopes LH
Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
[TBL] [Abstract][Full Text] [Related]
28. Renal cell carcinoma with rhabdoid features: an aggressive neoplasm with overexpression of p53.
Leroy X; Zini L; Buob D; Ballereau C; Villers A; Aubert S
Arch Pathol Lab Med; 2007 Jan; 131(1):102-6. PubMed ID: 17227108
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma.
Yildiz E; Gokce G; Kilicarslan H; Ayan S; Goze OF; Gultekin EY
BJU Int; 2004 May; 93(7):1087-93. PubMed ID: 15142169
[TBL] [Abstract][Full Text] [Related]
30. Abnormal expression of MDM-2 in breast carcinomas.
Bueso-Ramos CE; Manshouri T; Haidar MA; Yang Y; McCown P; Ordonez N; Glassman A; Sneige N; Albitar M
Breast Cancer Res Treat; 1996; 37(2):179-88. PubMed ID: 8750585
[TBL] [Abstract][Full Text] [Related]
31. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
[TBL] [Abstract][Full Text] [Related]
32. The predictive value of p53, MDM-2, cyclin D1 and Ki67 in the progression from low-grade dysplasia towards carcinoma of the larynx.
Pignataro L; Capaccio P; Pruneri G; Carboni N; Buffa R; Neri A; Ottaviani A
J Laryngol Otol; 1998 May; 112(5):455-9. PubMed ID: 9747474
[TBL] [Abstract][Full Text] [Related]
33. BUB1B Overexpression Is an Independent Prognostic Marker and Associated with CD44, p53, and PD-L1 in Renal Cell Carcinoma.
Sekino Y; Han X; Kobayashi G; Babasaki T; Miyamoto S; Kobatake K; Kitano H; Ikeda K; Goto K; Inoue S; Hayashi T; Teishima J; Sakamoto N; Sentani K; Oue N; Yasui W; Matsubara A
Oncology; 2021; 99(4):240-250. PubMed ID: 33588420
[TBL] [Abstract][Full Text] [Related]
34. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma.
Soslow RA; Altorki NK; Yang G; Xie D; Yang CS
Mod Pathol; 1999 Jun; 12(6):580-6. PubMed ID: 10392633
[TBL] [Abstract][Full Text] [Related]
35. Transition from in situ to invasive testicular germ cell neoplasia is associated with the loss of p21 and gain of mdm-2 expression.
Datta MW; Macri E; Signoretti S; Renshaw AA; Loda M
Mod Pathol; 2001 May; 14(5):437-42. PubMed ID: 11353054
[TBL] [Abstract][Full Text] [Related]
36. Expression of bcl-2, p53 oncoprotein, and proliferating cell nuclear antigen in renal cell carcinoma.
Sejima T; Miyagawa I
Eur Urol; 1999; 35(3):242-8. PubMed ID: 10072628
[TBL] [Abstract][Full Text] [Related]
37. p53, mdm2, and p21 expression in oral squamous cell carcinomas: relationship with clinicopathologic factors.
Yanamoto S; Kawasaki G; Yoshitomi I; Mizuno A
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2002 Nov; 94(5):593-600. PubMed ID: 12424454
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in astrocytic gliomas and their correlation to cell proliferation.
Dietzmann K; von Bossanyi P; Sallaba J; Kirches E; Synowitz HJ; Warich-Kirches M
Gen Diagn Pathol; 1996 May; 141(5-6):339-44. PubMed ID: 8780933
[TBL] [Abstract][Full Text] [Related]
39. Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics.
Momand J; Zambetti GP
Oncogene; 1996 Jun; 12(11):2279-89. PubMed ID: 8649767
[TBL] [Abstract][Full Text] [Related]
40. Malignant mixed Müllerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Sullivan S; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):18-24. PubMed ID: 9454654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
